anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The MI regimen was designed to achieve projected serum trough concentrations of belatacept of approximately 20 μg/mL through Day 99, and approximately 5 μg/mL through Day 183 (10 mg/kg on Days 1, 5, 15, 29, 43, 57, 71, 85, 113, 141, and 169). After Day 169, patients were reallocated and dosed to achieve projected trough serum concentrations of approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 197). Those patients who received belatacept every 8 weeks received placebo infusions on scheduled treatment dates between infusions of active drug to maintain the blind between treatment regimens. Patients initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the patient was able to tolerate medications by mouth. Corticosteroids given daily.
A dispenser comprises a compressible volume 1 containing a shear thinning and thixotropic viscous liquid or gel to be dispensed, the compressible volume 1 having an outlet 5, a plurality of openings are provided in the outlet 5, such that upon compression of the compressible volume 1, the liquid or gel is forced out through the plurality of openings. The viscous liquid or gel may be a gastrointestinal pharmaceutical product, the product may be a reflux suppressant, which may contain a liquid alginate. The product may be a pharmaceutical composition for the treatment of disorders of the oesophagus, for the treatment of reflux oesophagitis, gastritis, or dyspepsia. The compressible volume 1 may be provided by a squeezable bottle. A screw cap 2 may be provided which may fit over the complementary screw thread 3 on a neck of the bottle 1, the screw cap 2 may be provided with a flip up lid 4. The outlet with a plurality of openings may be provided by a metal mesh pad 5 which may be retained across the top of the bottle 1 and may be sandwiched between a shoulder on the lid 2 and the top of the bottle 1, or the mesh 5 may be an integral part of the cap 2.
Volunteers randomized into SHPT will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
PCT No. PCT/CA91/00341 Sec. 371 Date Apr. 12, 1993 Sec. 102(e) Date Apr. 12, 1993 PCT Filed Sep. 20, 1991 PCT Pub. No. WO92/05252 PCT Pub. Date Apr. 2, 1992A modified DNA sequence encoding full length cystic fibrosis transmembrane conductance regulator protein is provided to facilitate propagation and/or expression of the protein in living cells and in particular, bacterial cells. The modified DNA sequence comprises at least one of the 13 base pair repeat of exon 6b of the normal gene encoding the conductance regulator protein, as one or more normal nucleotides of the 13 base repeat substituted with an alternate nucleotide which, however, continues to code for the corresponding normal amino acid. Mammalian cells transfected with a vector containing the modified DNA sequence enhances chlorine conductance through the cell wall.
CATHAR is a prospective, open-label, pilot, phase 2 study with independent evaluation of all outcomes. The trial is based on a Bayesian design by incorporating historical information for the control group for all analyses.
A lesion detection ensemble machine learning model architecture comprising a plurality of trained machine learning (ML) computer models is provided. A first decoder of a lesion detection ML model processes a medical image input to generate a first lesion mapping prediction. A second decoder of the lesion detection ML model processes the medical image input to generate a second lesion mapping prediction. Combinational logic combines the first and second lesion mapping predictions to generate a combined prediction. Final lesion mapping output logic generates a final lesion prediction based on the combined lesion mapping prediction. The final lesion mapping output logic outputs the final lesion prediction for further downstream computing operations. The first decoder is trained with a first loss function that is configured to counterbalance a training of the second decoder that is trained using a second loss function different from the first loss function.
The primary purpose of this line of research is to investigate the effects of carbon fiber custom dynamic orthosis (CDO) design on the forces and contact stress at the ankle, with the goal of reducing the development of post traumatic osteoarthritis (PTOA) in the ankle. Research suggests that ankle arthritis develops, in part, due to increased contact stresses within the ankle joint following fracture. It is expected that reducing articular contact stress at the ankle has the potential to delay or prevent the development of PTOA. CDOs have been shown to significantly improve function following extremity injury, and show promise for offloading the injured limb after severe lower extremity injuries. Therefore, the proposed effort is designed to evaluate how different CDO design factors influence offloading and therefore the reduction of forces and articular contact stress at the ankle.

Adult participants will be evaluated while wearing carbon fiber braces of varied geometry. The primary dependent measure is ankle joint contact stress. Following consent and enrollment computerized tomography (CT) images will be used to determine the geometry of the joint articular surfaces. Ankle contact stress will be calculated using discrete element analysis and biomechanical data collected in subsequent data collection.

Participants will be cast and fit for three CDOs with varied geometry. Participants will be blinded to the design variation of each device and will only know them as CDO-A, CDO-B, or CDO-C. Testing will be completed under 4 conditions: No-CDO, CDO-A, CDO-B, CDO-C, with each bracing condition (A/B/C) representing a CDO design variant. Physical performance measures will incorporate tests of agility, speed, and lower limb power to ensure that changes to device design do not negatively affect physical function. Questionnaires will be used to evaluate participants' current and desired activity level, pain with and without CDO use, satisfaction with the devices, perception of comfort and smoothness between devices, and preference between CDOs. Semi-structured interviews will be completed to fully capture the participant's perspective. Lower limb forces and motion will be assessed using a computerized motion capture system and force plates in the floor. Forces between the foot and CDO will be measured using force sensing insoles, and muscle activity data will be collected using surface electromyography. Devices will be mechanically tested, and participant demographic and anthropometric data will be recorded.
SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASESThe invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino- terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. FIG. I
<P>PROBLEM TO BE SOLVED: To provide a cleansing method capable of carrying out cleansing suitable even under use environment in which water is interposed, having good elimination of make-up, excellent in massage property during use and hardly feeling tackiness to the skin during massage.  <P>SOLUTION: The cleansing method comprises carrying out elimination of make-up by adding water to a composition comprising (A) a nonionic surfactant having 8-12 HLB and (B) a transparent liquid oily composition comprising a liquid oil in the case the composition having a temperature region which does not become clouded at 25-35 °C is used as a cleansing agent when 30 pts. wt. water is added to 100 pts. wt. composition.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE: The Oncotype DX (ODX) test is a commercially available molecular test for breast cancer assay that provides prognostic and predictive breast cancer recurrence information for hormone positive, HER2-negative patients. The aim of this study is to propose a novel methodology to assist physicians in their decision-making.
METHODS: A retrospective study between 2012 and 2020 with 333 cases that underwent an ODX assay from three hospitals in the Bourgogne Franche-Comté region (France) was conducted. Clinical and pathological reports were used to collect the data. A methodology based on distributional random forest was developed to predict the ODX score classes (ODX [Formula: see text] and ODX [Formula: see text]) using 9 clinico-pathological characteristics. This methodology can be used particularly to identify the patients of the training cohort that share similarities with the new patient and to predict an estimate of the distribution of the ODX score.
RESULTS: The mean age of participants is 56.9 years old. We have correctly classified [Formula: see text] of patients in low risk and [Formula: see text] of patients in high risk. The overall accuracy is [Formula: see text]. The proportion of low risk correct predicted value (PPV) is [Formula: see text]. The percentage of high risk correct predicted value (NPV) is approximately [Formula: see text]. The F1-score and the Area Under Curve (AUC) are of 0.87 and 0.759, respectively.
CONCLUSION: The proposed methodology makes it possible to predict the distribution of the ODX score for a patient. This prediction is reinforced by the determination of a family of known patients with follow-up of identical scores. The use of this methodology with the pathologist's expertise on the different histological and immunohistochemical characteristics has a clinical impact to help oncologist in decision-making regarding breast cancer therapy.
INTRODUCTION: Anastomotic leak (AL) remains a severe complication following colorectal surgery, leading to increased morbidity and mortality, particularly in cases of delayed diagnosis. Existing diagnostic methods, including computed tomography (CT) scans, contrast enemas, endoscopic examinations, and reoperations can confirm AL but lack strong predictive value. Early detection is crucial for improving patient outcomes, yet a definitive and reliable predictive test, or "gold standard," is still lacking.
METHODS: A comprehensive PubMed review was focused on CT imaging, serum levels of C-reactive protein (CRP), and procalcitonin (PCT) to assess their predictive utility in detecting AL after colorectal resection. Three independent reviewers evaluated eligibility, extracted data, and assessed the methodological quality of the studies.
RESULTS: Summarized in detailed tables, our analysis revealed the effectiveness of both CRP and PCT in the early detection of AL during the postoperative period. CT imaging, capable of identifying fluid collection, pneumoperitoneum, extraluminal contrast extravasation, abscess formation, and other early signs of leak, also proved valuable.
CONCLUSIONS: Considering the variability in findings and statistics across these modalities, our study suggests a personalized, multimodal approach to predicting AL. Integrating CRP and PCT assessments with the diagnostic capabilities of CT imaging provides a nuanced, patient-specific strategy that significantly enhances early detection and management. By tailoring interventions based on individual clinical characteristics, surgeons can optimize patient outcomes, reduce morbidity, and mitigate the consequences associated with AL after colorectal surgery. This approach emphasizes the importance of personalized medicine in surgical care, paving the way for improved patient health outcomes.
Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio \<0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced 2 or more exacerbations requiring oral steroids/antibiotics treatment and/or hospitalisation in the previous 12 months.
PCT No. PCT/JP93/00586 Sec. 371 Date Jan. 3, 1994 Sec. 102(e) Date Jan. 3, 1994 PCT Filed Apr. 30, 1993 PCT Pub. No. WO93/22448 PCT Pub. Date Nov. 11, 1993.In a process of production of a useful protein by culturing a human embryonal kidney cell-derived 293 strain which is introduced with a useful protein-expressing gene, it becomes possible to obtain a culture fluid containing the useful protein in a high concentration using an extremely small amount of the medium, by carrying out a fed-batch culture and adding a sugar or a sugar and a calcium in a specified stage of the culture.
Patients receive guadecitabine SC on days 1-4 and pembrolizumab IV over 30 minutes on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
The damage caused by the white-back planthopper (WBPH, Sogatella furcifera) and brown planthopper (BPH, Nilaparvata lugens), as well as southern rice black-streaked dwarf virus (SRBSDV), considerably decreases the grain yield of rice. Identification of rice germplasms with sufficient resistance to planthoppers and SRBSDV is essential to the breeding and deployment of resistant varieties and, hence, the control of the pests and disease. In this study, 318 rice accessions were evaluated for their reactions to the infestation of both BPH and WBPH at the seedling stage using the standard seed-box screening test method; insect quantification was further conducted at the end of the tillering and grain-filling stages in field trials. Accessions HN12-239 and HN12-328 were resistant to both BPH and WBPH at all tested stages. Field trials were conducted to identify resistance in the collection to SRBSDV based on the virus infection rate under artificial inoculation. Rathu Heenati (RHT) and HN12-239 were moderately resistant to SRBSDV. In addition, we found that WBPH did not penetrate stems with stylets but did do more probing bouts and xylem sap ingestion when feeding on HN12-239 than the susceptible control rice Taichung Native 1. The resistance of rice accessions HN12-239, HN12-328, and RHT to BPH, WBPH, and/or SRBSDV should be valuable to the development of resistant rice varieties.
The invention discloses an externally used pilose antler polypeptide traditional Chinese medicine composition for men. The externally used pilose antler polypeptide traditional Chinese medicine composition is prepared from, by mass, 0.01-10 parts of pilose antler, 0.01-10 parts of deer blood, 1-8 parts of spongilla, 1-8 parts of radix sophorae flavescentis, 1-8 parts of curculigo orchioides, 1-8 parts of herba cistanche, 1-8 parts of radix angelica sinensis, 0.5-8 parts of ginseng, 2-8 parts of epimedium and 1-8 parts of clove. A penetration enhancer and pharmaceutically acceptable auxiliary materials can be also added. The high-quality pilose antler and the deer blood are adopted and are scientifically compatible with the spongilla, the radix sophorae flavescentis, the curculigo orchioides, the herba cistanche, the radix angelica sinensis, the ginseng, the epimedium and the clove having a remarkable effect, and the effects of the active ingredients of the pilose antler and the deer blood are played to the most degree. The transdermal absorption is the key for the externally used pilose antler polypeptide traditional Chinese medicine composition. On one hand, the molecular weights of the active ingredients of the pilose antler and the deer blood are limited in an easy absorption range; on the other hand, the clove, the curculigo orchioides and the epimedium are added based on the raw materials the pilose antler and the deer blood, the three traditional Chinese medicines are the effective ingredients of the traditional Chinese medicine composition and meanwhile are also good penetration enhancers, and the independent usage effects of the pilose antler and the deer blood are improved.
BACKGROUND: Limb ischemia-reperfusion is a common phenomenon in clinical surgery, which disrupts the balanced physiological response process and ultimately leads to changes in intracellular viscosity. Intracellular viscosity is an important microenvironmental parameter that affects the normal function of organisms, and its level is closely related to many diseases. In addition, oxidative stress in the lower limbs can impair body function, and changes in pressure can lead to changes in the viscosity of limb tissues. Therefore, it is necessary to develop effective tools to detect changes in intracellular viscosity and visualize the progression of hind limb ischemia-reperfusion injury.
RESULTS: In order to solve this problem, a near infrared viscometry sensitive fluorescence probe (PH-XQ) with long emission wavelength and stable luminescence performance was designed and synthesized by using oxanthracene derivatives and malononitrile. The fluorescence probe (PH-XQ) has excellent selectivity, high sensitivity, low toxicity, high biocompatibility and excellent detection performance. The fluorescence intensity of the PH-XQ probe at 667 nm is highly sensitive to the change of viscosity. With the increase of viscosity, the fluorescence intensity of probe PH-XQ was significantly enhanced, and the fluorescence enhancement ratio was about 14-fold. In addition, PH-XQ can detect not only changes in viscosity between normal cells and drug-induced inflammatory cells, but also changes in the viscosity of the hind limbs of normal mice and mice after ischemia reperfusion.
SIGNIFICANCE: In particular, we are the first to successfully detect changes in handlimb viscosity after ischemia-reperfusion in mice using a probe. This study clearly elucidates changes in viscosity during ischemia-reperfusion of mouse limbs, providing favorable support for the relationship between viscosity and related diseases, and further providing a potential tool for the diagnosis of viscosity-related diseases.
Participant will receive a single oral dose of 4 study treatments with the sequences of BDAC. The washout period will be \>= 5 days between each dose.
The dosage should be initiated at a low level and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. Trazodone HCl should be taken shortly after a meal or light snack. Symptomatic relief may be seen during the first week with optimal antidepressant effects typically evident within two weeks. Twenty-five percent of those who respond to trazodone HCl require more than two weeks (up to four weeks) of drug administration.

Usual Adult Dosage: An initial dose of 150 mg/day in divided doses is suggested. The dose may be increased by 50 mg/day every three to four days. The maximum dose for outpatients usually should not exceed 400 mg/day in divided doses. Inpatients (i.e., more severely depressed patients) may be given up to but not in excess of 600 mg/day in divided doses.

Maintenance: Dosage during prolonged maintenance therapy should be kept at the lowest effective level. Once an adequate response has been achieved, dosage may be gradually reduced, with subsequent adjustment depending on therapeutic response.

Although there has been no systematic evaluation of the efficacy of trazodone beyond 6 weeks, it is generally recommended that a course of antidepressant drug treatment should be continued for several months.
The present invention relates to a pharmaceutical composition for the prevention and treatment of COVID-19 containing a Platycodon grandiflorum extract and platycodin D as active components. More specifically, the present invention relates to a pharmaceutical composition for prevention and treatment of COVID-19 by inhibiting cellular infection of COVID-19 and inhibiting the production of intracellular infectious virus of platicodin D, a component contained in Platycodon grandiflorum, and a method for preventing and treating COVID-19 by using the pharmaceutical composition. The Platycodon grandiflorum extract or platycodin D, an active component thereof exhibits a remarkable inhibitory effect on cell entry and cell infection of coronavirus, and is confirmed to exhibit a more pronounced effect than chloroquine, camostat, and nafamostat, which are treatment candidates through inhibition of cell entry and cell infection of coronavirus. Through the same, the pharmaceutical composition can be usefully used to prevent coronavirus or to treat early stages of infection. In addition, the Platycodon grandiflorum extract or platycodin D inhibits the cleavage of the spike protein important for infection during packaging of coronavirus, thereby inhibiting the proliferation and spread of the infectious coronavirus in cells. Therefore, the composition of the present invention is useful for the prevention and treatment of coronavirus.